Diverse and Expanding Pipeline of RNA-, Antibody- and Enzyme-Based Programs
At Entrada Therapeutics, we are driven to transform the lives of patients by establishing EEV-therapeutics as a new class of medicines. We are already developing potential treatments across multiple devastating diseases with a simple and scalable platform designed to translate from preclinical to clinical development.
